SCHEMBL22930788

SCHEMBL22930788

CC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1OP(=O)(S)OCC1O[C@@H](n2cnc3c(N)ncnc32)[C@H](OP(=O)(O)S)[C@@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 8/20 0.60
▸ NT5E P21589 1/20 0.60
▸ ADORA1 P30542 2/20 0.57
▸ DNPH1 O43598 1/20 0.57
▸ PRKAB2 O43741 1/20 0.57
▸ TRPM2 O94759 1/20 0.57
▸ LDHA P00338 1/20 0.57
▸ ADRB2 P07550 1/20 0.57
▸ FBP1 P09467 1/20 0.57
▸ SRC P12931 1/20 0.57
▸ P2RY2 P41231 1/20 0.57
▸ P2RY1 P47900 1/20 0.57
▸ PRKAG1 P54619 1/20 0.57
▸ PRKAA2 P54646 1/20 0.57
▸ PDE4D Q08499 1/20 0.57
▸ KCNH2 Q12809 1/20 0.57
▸ PRKAA1 Q13131 1/20 0.57
▸ PDE3A Q14432 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ TAS1R3 Q7RTX0 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23624674 0.87 ADORA1 (0.61) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL22930637 0.87 NT5E (0.61) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL18937556 0.83 RNASEL (0.60) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL22326769 0.82 RNASEL (0.73) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL13020487 0.82 RNASEL (0.73) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL24722324 0.82 RNASEL (0.57) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL22381966 0.82 NT5E (0.80) NT5EADORA1DNPH1PRKAB2TRPM2
SCHEMBL22930754 0.81 P2RY1 (0.59) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL23476718 0.81 NT5E (0.55) RNASELNT5EADORA1DNPH1PRKAB2
SCHEMBL23476794 0.81 NT5E (0.56) RNASELNT5EADORA1DNPH1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906930-B2 Compositions and methods for activating “stimulator of interferon gene”-dependent signalling CHINOOK THERAPEUTICS, INC. (US) 2021-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906930-B2 Compositions and methods for activating “stimulator of interferon gene”-dependent signalling STING1, IRF3, CGAS RNASEL 1252/4885NT5E 83/4885ADORA1 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback